These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Pneumococcal infections -- clinical features, prevention and current therapy. Interview with Dr. Endre Ludwig by Anna Radnai]. Ludwig E Orv Hetil; 2013 Jan; 154(3):118-20. PubMed ID: 23315227 [No Abstract] [Full Text] [Related]
29. Treatment of severe meningitis due to antibiotic-resistant Streptococcus pneumoniae. Hudson BJ; Havryk A; Abel SJ; Fernandes CJ Med J Aust; 1999 Oct; 171(8):447-8. PubMed ID: 10590755 [No Abstract] [Full Text] [Related]
30. Cefotaxime in the treatment of pneumococcal pneumonia. Jenkinson SG; Briggs MS; Bryn RD J Antimicrob Chemother; 1980 Sep; 6 Suppl A():177-80. PubMed ID: 6252152 [No Abstract] [Full Text] [Related]
31. Action plan for drug-resistant Streptococcus pneumoniae. The DRSP Working Group. Cetron MS; Jernigan DB; Breiman RF Emerg Infect Dis; 1995; 1(2):64-5. PubMed ID: 8903164 [No Abstract] [Full Text] [Related]
32. [Pneumococcus and quinolone resistance]. Bello S; Torres A Arch Bronconeumol; 2003 Mar; 39(3):97-100. PubMed ID: 12622966 [No Abstract] [Full Text] [Related]
33. Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Bradley JS; Kaplan SL; Klugman KP; Leggiadro RJ Pediatr Infect Dis J; 1995 Dec; 14(12):1037-41. PubMed ID: 8745014 [No Abstract] [Full Text] [Related]
34. Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin. Wise KA; Bedford M; Wadhwa SS; Slobodniuk R Pathology; 1995 Apr; 27(2):165-7. PubMed ID: 7567146 [TBL] [Abstract][Full Text] [Related]
35. Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases. Naba MR; Araj GF; Baban TA; Tabbarah ZA; Awar GN; Kanj SS J Infect Public Health; 2010; 3(3):113-7. PubMed ID: 20869671 [TBL] [Abstract][Full Text] [Related]
36. [Empyema due to erythromycin-resistant Pneumococcus]. Sánchez-Torrero JF; Fernández Capitán MC; Arnalich F; Díez Enciso M; Pacios E An Med Interna; 1992 Apr; 9(4):208-9. PubMed ID: 1581464 [No Abstract] [Full Text] [Related]
37. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Harwell JI; Brown RB Chest; 2000 Feb; 117(2):530-41. PubMed ID: 10669700 [TBL] [Abstract][Full Text] [Related]
38. Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections. Lister PD Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S18-25. PubMed ID: 7729467 [TBL] [Abstract][Full Text] [Related]
39. [Various prospective approaches to the treatment of nonspecific lung diseases]. Sil'vestrov VP; Vanina NF Ter Arkh; 1980; 52(3):3-12. PubMed ID: 6966837 [No Abstract] [Full Text] [Related]
40. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on "Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy". Yu VL Arch Intern Med; 2011 Jan; 171(2):172-3. PubMed ID: 21263107 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]